Clinical trials: Parasitic Infections
Malaria, Bacterial Co-infection
Host Immunity, Plasmodium and Pathogens Co-Infections
Few studies have focused on malaria co-infections, mainly caused by Plasmodium falciparum, occurring mainly in children under 5 years of age in sub-Saharan Africa.
- Trial name
- HIPPI (NCT06769815)
- Testing
- Blood sample, Urine sample, oropharyngeal sample
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Scabies
A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies
This phase III study was conducted to establish the clinical bioequivalence of Permethrin Cream 5% and Elimite™ in the treatment of scabies following a single application.
- Trial name
- NCT03973775
- Testing
- Permethrin Cream 5%
- Where
- 5 sites in United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Saptalis Pharmaceuticals LLC
African Trypanosomiasis
Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Human African Trypanosomiasis or sleeping sickness has made a spectacular return during the last decade, and in many places the demand largely surpasses the capacities of the treatment centers.
- Trial name
- NCT00803933
- Testing
- DB289, Pentamidine
- Where
- 2 sites in Republic of the Congo
- Volunteers
- 111 people
- Sponsor
- Immtech Pharmaceuticals, Inc
Schistosoma Hematobium Infection, Schistosomiasis Mansoni
Safety and Efficacy of Mirazid for Schistosomiasis Treatment
Clinical Trial Phase:Phase III Primary Objectives: Compare Mirazid and Praziquantel cure rates for both Schistosoma species. Compare Mirazid and Praziquantel effect in lowering the intensity of infection for both Schistosoma…
- Trial name
- PHAR0211 (NCT01529710)
- Testing
- Myrrh
- Where
- 2 sites in Egypt
- Volunteers
- 200 people
- Sponsor
- Pharco Pharmaceuticals
Malaria, Falciparum
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria
The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.
- Trial name
- NCT07545681
- Testing
- GSK3772701 600 mg, GSK3772701 900 mg, GSK3772701 150 mg
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Trichomoniasis
Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Tinidazole 500 mg Tablet under fed conditions.
- Trial name
- NCT01591889
- Testing
- Tinidazole
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Paludism
Evaluation of the STANDARD G6PD Rapid Test for Assaying the Enzymatic Activity of G6PD in French Guiana
In French Guiana, malaria is endemic and two species predominate: P. falciparum and P. vivax. The treatments against Plasmodium vivax malaria are: nivaquine for 3 days against circulating blood parasites and primaquine for 14…
- Trial name
- G6PD facile (NCT04698980)
- Testing
- blood samples (venous and capillary at the fingertip)
- Where
- French Guiana
- Volunteers
- 150 people
- Sponsor
- Institut Pasteur
Malaria, Vivax
Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)
The study aims to provide evidence of retinal safety to support the use of tafenoquine as a potential single dose radical cure treatment for patients with Plasmodium vivax (P.
- Trial name
- NCT02658435
- Testing
- Tafenoquine 150 mg
- Where
- 3 sites in United States
- Volunteers
- 486 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pediculosis Capitis, Lice Infestations
A Study to Evaluate the Efficacy and Safety of a Leave-in Spray in Subjects With Head Lice Infestation
The purpose of this study is to evaluate the safety and efficacy of Vamousse Spray 'n' Go, compared to a 1% Permethrin control shampoo, in the treatment of head lice.
- Conditions
- Pediculosis Capitis, Lice Infestations, Head Lice
- Trial name
- NCT05565820
- Testing
- Vamousse Spray 'n' Go, Nix Creme Rinse Lice Treatment
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Alliance Pharmaceuticals
Malaria, Vivax
Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria
The aim of the present study is to investigate the efficacy, safety and tolerability of a therapeutic course of Eurartesim® in travellers who contracted malaria due to infection by P. vivax in endemic countries.
- Trial name
- NCT02110784
- Testing
- Eurartesim tablets
- Where
- 13 sites in France, Germany and 5 more
- Volunteers
- 27 people
- Sponsor
- Alfasigma S.p.A.
Malaria
Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance
Primary Objective: To demonstrate the non-inferiority, in terms of clinical and parasitological efficacy on Day 14, of administration of Arsucam® as a single daily intake versus two daily intakes.
- Trial name
- ATOL (NCT00445796)
- Testing
- Artesunate, Amodiaquine
- Where
- 2 sites in Cameroon, Senegal
- Volunteers
- 300 people
- Sponsor
- Sanofi
Head Lice Infestation
Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation
Purpose of this study is to evaluate the efficacy of at-home administration of a single application of abametapir lotion 0.74% w/w for the treatment of head lice.
- Trial name
- NCT02062060
- Testing
- Abametapir Lotion 0.74% w/w, Vehicle Lotion
- Where
- 7 sites in United States
- Volunteers
- 325 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Malaria, Vivax
A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate
This will be a single-centre, 5-cohort, randomized open-label, parallel-group study in healthy volunteer subjects. This study aims to provide sufficient pharmacokinetic (PK) evidence to support the safe usage of Tafenoquine (TQ)…
- Trial name
- NCT02184637
- Testing
- Tafenoquine, Dihydroartemisinin + Piperaquine tetraphosphate, Artemether + Lumefantrine
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults
MALARIA-092 (NCT03162614) study was designed to evaluate the efficacy, immunogenicity and safety of various dose schedules and formulations of GSK Biologicals' candidate malaria vaccine (RTS,S/AS01E) in healthy malaria-naïve…
- Trial name
- NCT03824236
- Testing
- RTS,S/AS01E (SB257049)
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
This is a randomized, double blind, placebo-controlled, single site, trial of a condensed regimen of PfSPZ Vaccine administered on Days 1, 8 and 29 by direct venous inoculation (DVI) to assess safety, tolerability, immunogenicity…
- Trial name
- NCT04966871
- Testing
- PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks
Primary objective: to demonstrate the non-inferiority of PCR adjusted adequate clinical and parasitological response at D28 of artesunate + amiodaquine versus artemether + lumefantrine, based on the first malaria attack of each…
- Trial name
- NCT00540410
- Testing
- Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination), Coartem® (arthemether+ lumefantrine)
- Where
- Senegal
- Volunteers
- 366 people
- Sponsor
- Sanofi
Chagas Disease
Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg
Study to assess the relative Bioavailability To assess the relative bioavailability of three formulations of nifurtimox 30 mg tablets exhibiting different in vitro dissolution profiles To assess the pharmacokinetics (PK) of…
- Trial name
- NCT03350295
- Testing
- Nifurtimox (Lampit, BAYA2502)
- Where
- Argentina
- Volunteers
- 48 people
- Sponsor
- Bayer
Malaria, Vivax
Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria
Tafenoquine (TQ) is an 8-aminoquinoline anti-malarial drug which is in development as a single-dose treatment for the radical cure of P.vivax malaria when given with standard doses of chloroquine.
- Trial name
- NCT02802501
- Testing
- Tafenoquine, Primaquine, Dihydroartemisinin-piperaquine (DHA-PQP)
- Where
- Indonesia
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Cryptosporidiosis, HIV Infections
Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients
This protocol provides for the availability of spiramycin under compassionate-use conditions for the treatment of chronic diarrhea due to cryptosporidium in patients with a compromised immune system, thus deriving additional…
- Trial name
- NCT00002062
- Testing
- Spiramycin
- Where
- United States
- Sponsor
- Rhone-Poulenc Rorer
Malaria, Healthy Participants
A Study of Oral E1018 in Healthy Adult Participants
The primary purpose of the study is to evaluate the safety and tolerability of single ascending oral doses of E1018 in healthy adult participants and to evaluate the pharmacokinetics (PK) of E1018 in plasma and urine after single…
- Trial name
- NCT06854042
- Testing
- E1018
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.